Publications scientifiques

External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry

Auteurs : Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prévot G, Chaouat A, Picard F, Horeau-Langlard D, Bourdin A, Jutant EM, Beurnier A, Jevnikar M, Jaïs X, Simonneau G, Montani D, Sitbon O, Humbert M.

Sources : Eur Respir J. 2021 Nov 4:2102419.

Thoracoscopic surgery for congenital lung malformations: Does previous infection really matter?

Auteurs : Elhattab A, Elsaied A, Wafa T, Jugie M, Delacourt C, Sarnacki S, Aly K, Khen-Dunlop N.

Sources : J Pediatr Surg. 2021 Nov;56(11):1982-1987.

Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload

Auteurs : Lambert M, Mendes-Ferreira P, Ghigna MR, LeRibeuz H, Adão R, Boet A, Capuano V, Rucker-Martin C, Brás-Silva C, Quarck R, Domergue V, Vachiéry JL, Humbert M, Perros F, Montani D, Antigny F.

Sources : Cardiovasc Res. 2021 Nov 1;117(12):2474-2488.

RaDiCo, the French national research program on rare disease cohorts

Auteurs : Amselem S, Gueguen S, Weinbach J, Clement A, Landais P; RaDiCo Program.

Sources : Orphanet J Rare Dis. 2021 Oct 29;16(1):454.

Exposure to inorganic particles in paediatric sarcoidosis: the PEDIASARC study

Auteurs : Nathan N, Montagne ME, Macchi O, Rosental PA, Chauveau S, Jeny F, Sesé L, Abou Taam R, Brocvielle M, Brouard J, Catinon M, Chapelon-Abric C, Cohen-Aubart F, Delacourt C, Delestrain C, Deschildre A, Dossier A, Epaud R, Haroche J, Houdouin V, Israel-Biet D, Juvin K, Le Jeune S, Lionnet F, Meinzer U, Mittaine M, Nunes H, Mattioni S, Naccache JM, Odièvre MH, Vincent M, Clement A, Valeyre D, Cavalin C; French Sarcoidosis Group and the Silicosis Research Group.

Sources : Thorax. 2021 Oct 21: thoraxjnl-2021-217870.

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis

Auteurs : Nasser M, Si-Mohamed S, Turquier S, Traclet J, Ahmad K, Philit F, Bonniaud P, Chalabreysse L, Thivolet-Béjui F,Cottin V.

Sources : Orphanet J Rare Dis. 2021 Oct 9;16(1):419.

Post hoc Analysis of Clinical Outcomes in Placebo- and Pirfenidone-Treated Patients with IPF Stratified by BMI and Weight Loss

Auteurs : Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Yang M, Morgenthien E, Kirchgaessler KU, Cottin V.

Sources : Respiration. 2021 Oct 5:1-13.

Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden

Auteurs : Lancaster L, Bonella F, Inoue Y, Cottin V, Siddall J, Small M, Langley J.

Sources : Respirology. 2021 Oct 5. Doi: 10.1111/resp.14154.

Pulmonary hypertension : A rare but severe complication of common variable immunodeficiency

Auteurs : Thoré P, Humbert M, Montani D.

Sources : Ann Allergy Asthma Immunol. 2021 Oct;127(4):512-513. Doi: 10.1016/j.anai.2021.06.016.

Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension

Auteurs : Boucly A, Savale L, Jaïs X, Bauer F, Bergot E, Bertoletti L, Beurnier A, Bourdin A, Bouvaist H, Bulifon S, Chabanne C, Chaouat A, Cottin V, Dauphin C, Degano B, De Groote P, Favrolt N, Feng Y, Horeau-Langlard D, Jevnikar M, Jutant EM, Liang Z, Magro P, Mauran P, Moceri P, Mornex JF, Palat S, Parent F, Picard F, Pichon J, Poubeau P, Prévot G, Renard S, Reynaud-Gaubert M, Riou M, Roblot P, Sanchez O, Seferian A, Tromeur C, Weatherald J, Simonneau G, Montani D, Humbert M, Sitbon O.

Sources : Am J Respir Crit Care Med. 2021 Oct 1;204(7):842-854. Doi: 10.1164/rccm.202009-3698OC.